Ge Healthcare Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GE HEALTHCARE, and when can generic versions of GE HEALTHCARE drugs launch?
GE HEALTHCARE has fifty approved drugs.
There are four US patents protecting GE HEALTHCARE drugs.
There are eighty patent family members on GE HEALTHCARE drugs in twenty-six countries and one hundred and thirty-six supplementary protection certificates in eighteen countries.
Summary for Ge Healthcare
International Patents: | 80 |
US Patents: | 4 |
Tradenames: | 58 |
Ingredients: | 39 |
NDAs: | 50 |
Drug Master File Entries: | 5 |
Drugs and US Patents for Ge Healthcare
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ge Healthcare | DICOPAC KIT | cyanocobalamin; cyanocobalamin co-57; cyanocobalamin co-58 | N/A;N/A | 017406-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Ge Healthcare | OMNISCAN | gadodiamide | INJECTABLE;INJECTION | 020123-001 | Jan 8, 1993 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Ge Healthcare | HYPAQUE SODIUM 20% | diatrizoate sodium | SOLUTION;URETERAL | 009561-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Ge Healthcare | ISOPAQUE 440 | calcium metrizoate; meglumine metrizoate; metrizoate magnesium; metrizoate sodium | INJECTABLE;INJECTION | 016847-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Ge Healthcare | HYPAQUE-CYSTO | diatrizoate meglumine | SOLUTION;URETHRAL | 016403-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Ge Healthcare | THALLOUS CHLORIDE TL 201 | thallous chloride tl-201 | INJECTABLE;INJECTION | 018110-002 | Feb 27, 1996 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ge Healthcare
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ge Healthcare | VISIPAQUE 320 | iodixanol | INJECTABLE;INJECTION | 020351-002 | Mar 22, 1996 | 4,278,654 | ⤷ Try a Trial |
Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-001 | Oct 25, 2013 | 7,351,401 | ⤷ Try a Trial |
Ge Healthcare | MPI DMSA KIDNEY REAGENT | technetium tc-99m succimer kit | INJECTABLE;INJECTION | 017944-001 | May 18, 1982 | 4,208,398 | ⤷ Try a Trial |
Ge Healthcare | VISIPAQUE 270 | iodixanol | INJECTABLE;INJECTION | 020351-001 | Mar 22, 1996 | 4,278,654 | ⤷ Try a Trial |
Ge Healthcare | VISIPAQUE 320 | iodixanol | INJECTABLE;INJECTION | 020351-002 | Mar 22, 1996 | 5,349,085 | ⤷ Try a Trial |
Ge Healthcare | OMNIPAQUE 240 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-002 | Dec 26, 1985 | 4,021,481 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Ge Healthcare Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Hong Kong | 1058041 | ⤷ Try a Trial |
Denmark | 1611115 | ⤷ Try a Trial |
Australia | 2008292201 | ⤷ Try a Trial |
Japan | 2004506723 | ⤷ Try a Trial |
Australia | 2011200667 | ⤷ Try a Trial |
South Korea | 101571572 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ge Healthcare Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2182988 | 2015006 | Norway | ⤷ Try a Trial | PRODUCT NAME: VIZAMYL; REG. NO/DATE: EU/1/14/941 20140822 |
1611115 | C 2015 004 | Romania | ⤷ Try a Trial | PRODUCT NAME: FLUTEMETAMOL (18 F) SAU O SARE, HIDRAT SAU SOLVAT ALACESTUIA ACCEPTABILEFARMACEUTIC; NATIONAL AUTHORISATION NUMBER: EU/1/14/941; DATE OF NATIONAL AUTHORISATION: 20140822; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/941; DATE OF FIRST AUTHORISATION IN EEA: 20140822 |
1948158 | 93075 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE SODIQUE SACUBITRIL VALSARTAN, C'EST-A-DIRE DE (3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3'-METHYL-2-(PENTANYOL(2''-(TETRAZOL-5-YLATE)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRATE) DE TRISODIUM HEMIPENTAHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123 |
2822954 | 1890030-8 | Sweden | ⤷ Try a Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625 |
2340828 | LUC00195 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE DE SEL DE SODIUM SACUBITRIL VALSARTAN, C'EST-A-DIRE (((S)-N-VALERYL-N-((2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-ESTER ETHYLIQUE D'ACIDE PENTANOIQUE))NA3 X H2O, DANS LEQUEL X EST 0 A 3; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123 |
2932970 | 1890039-9 | Sweden | ⤷ Try a Trial | PRODUCT NAME: DOLUTEGRAVIR SODIUM + RILPIVIRINE HYDROCHLORIDE; REG. NO/DATE: EU/1/18/1282 20180518 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.